List view / Grid view

Antimicrobials

 

news

ESCMID and ASM’s review need for new strategies and tactics to fight antimicrobial resistance

11 October 2016 | By Niamh Louise Marriott, Digital Content Producer

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the American Society for Microbiology (ASM) have just closed a joint conference in Vienna, which aimed to help researchers accelerate the development of new antimicrobials and to shed light on the challenges associated with antimicrobial resistance.

article

Flow cytometry: breaking bottlenecks in drug discovery and development

20 September 2016 | By ,

The discovery and development of novel drug candidates is a highly complex, time-consuming and expensive process. Pharmaceutical scientists and clinicians should, therefore, reevaluate and modify the existing standard platforms and increase their uptake of robust advanced technologies such as flow cytometry to overcome the bottlenecks in these processes...

news

ESCMID-ASM to review antimicrobial development process

27 June 2016 | By European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

ESCMID and ASM are jointly organising a conference to help researchers accelerate the development of new antimicrobials for drug-resistant infections...

article

Soligenix on IDR technology and SGX942

10 May 2016 | By Victoria White, Digital Content Producer

We discuss Innate Defense Regulator (IDR) technology with Soligenix's Chief Scientific Officer, Dr Oreola Donini, and find out more about SGX942...

article

The threat of antibiotic resistance

25 April 2016 | By Victoria White, Drug Target Review

We've created an infographic on the threat of antibiotic resistance, highlighting some of the recommendations made by the Review on Antimicrobial Resistance to date...

news

Time to renew the antibiotic arsenal

19 January 2016 | By Philippe Villain-Guillot, CEO, Nosopharm

Philippe Villain-Guillot, CEO, Nosopharm, discusses antimicrobial resistance and the challenges facing antibacterial drug discovery and development...

news

First patient enrolled in the New Drugs 4 Bad Bugs (ND4BB) programme

3 February 2015 | By Innovative Medicines Initiative (IMI)

Two years after the start of the Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) programme, the first patient has been enrolled into a Phase 2 trial sponsored by MedImmune, the global biologics research and development arm of AstraZeneca. The trial with MEDI4893 is among mechanically ventilated intubated…